ArticleInternational journal of molecular sciences2024

DGAT1 and DGAT2 Inhibitors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Benefits for Their Single or Combined Application.

Miriam Longo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.